Marathon Pharmaceuticals signals it will wind down after stirring a hornet’s nest with $89,000 Duchenne treatment
Marathon Pharmaceuticals has been quietly discussing plans to shutter its operations after kicking up a storm of controversy over an effort to market a cheap overseas steroid to the Duchenne muscular dystrophy community in the US at a list price of $89,000.
In an email out to a contact in the Duchenne muscular dystrophy community in late March, which I obtained from someone familiar with the situation, R&D director Tim Cunniff noted:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.